Synopsis

Source of validity: Scientific
Rating (out of 5): 2

7-Hydroxymatairesinol (HMR) is a plant lignan found primarily in Norway spruce. Its interest in osteoporosis stems from its phytoestrogenic properties, as HMR is metabolized in the human body into enterolactone, a compound with weak estrogen-like activity. Estrogen plays a crucial role in maintaining bone density, and postmenopausal osteoporosis is largely attributed to the decline in endogenous estrogen production. Preclinical studies have shown that HMR can positively influence bone metabolism. For example, animal studies (notably in ovariectomized rats, a common model for postmenopausal osteoporosis) have demonstrated that HMR supplementation can attenuate bone loss, improve bone microarchitecture, and alter markers of bone turnover in ways that suggest a protective effect.

However, clinical evidence in humans is currently limited. While some small-scale studies and pilot trials show that HMR supplementation increases circulating enterolactone levels, direct evidence of its efficacy in reducing fracture risk or significantly improving bone mineral density in humans is lacking. No large randomized controlled trials have been completed to establish its effectiveness for osteoporosis in humans. Therefore, while there is a plausible biological mechanism and supporting animal data, the direct scientific validation in human populations is insufficient at present, resulting in a modest evidence rating.

In summary, HMR's use for osteoporosis is scientifically motivated and supported by preclinical data, but more robust human clinical trials are needed before it can be recommended as a standard therapy.

More about 7-hydroxymatairesinol (HMR)
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by 7-hydroxymatairesinol (HMR)

Products containing 7-hydroxymatairesinol (HMR)